What is HC Wainwright’s Forecast for PLX FY2024 Earnings?

Protalix BioTherapeutics, Inc. (NYSE:PLX) – HC Wainwright issued their FY2024 EPS estimates for shares of Protalix BioTherapeutics in a note issued to investors on Monday, February 3rd. HC Wainwright analyst R. Selvaraju expects that the company will earn $0.01 per share for the year. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.02 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q4 2024 earnings at $0.06 EPS and FY2025 earnings at $0.19 EPS.

Separately, StockNews.com cut Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday.

Protalix BioTherapeutics Stock Up 6.0 %

NYSE:PLX opened at $2.67 on Wednesday. Protalix BioTherapeutics has a 12-month low of $0.82 and a 12-month high of $2.71. The stock’s 50 day moving average price is $2.01 and its two-hundred day moving average price is $1.43. The firm has a market capitalization of $196.59 million, a price-to-earnings ratio of -20.54 and a beta of 0.75.

Institutional Investors Weigh In On Protalix BioTherapeutics

A number of institutional investors have recently made changes to their positions in PLX. Y Intercept Hong Kong Ltd bought a new stake in Protalix BioTherapeutics in the 4th quarter valued at $35,000. XTX Topco Ltd bought a new stake in shares of Protalix BioTherapeutics in the third quarter valued at about $36,000. Cubist Systematic Strategies LLC acquired a new position in shares of Protalix BioTherapeutics in the second quarter valued at about $37,000. Sanctuary Advisors LLC acquired a new stake in Protalix BioTherapeutics in the 3rd quarter worth about $38,000. Finally, PFG Investments LLC bought a new stake in Protalix BioTherapeutics in the 4th quarter valued at about $39,000. Institutional investors own 16.53% of the company’s stock.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.